Biotricity Inc., a medical diagnostic and consumer healthcare technology company, announced that it is developing “Biopatch,” an ECG patch which it hopes to release in Q1 2019. An extension of the company’s Bioflux device, Biopatch offers an alternative to the 3-lead system which is ideal for patients with less complicated cardiac conditions. The patch leverages the capabilities of Bioflux and provides wireless arrhythmia monitoring for patients who are either at risk for, or diagnosed with, certain cardiac issues.
“We are developing Biopatch to make it easier for patients to use without compromising quality,” said Mr. Waqaas Al-Siddiq, Biotricity Founder and CEO. “As an extension of Bioflux, Biopatch will considerably expand our addressable market.”
ECG patches are less cumbersome to wear and easier for patients to use.
“Patients with complex issues who require Bioflux are a smaller sub-set of the larger cardiac monitoring market, so by introducing Biopatch we are widening our commercial reach and offering patients a more convenient monitoring solution with high usability.”
Continuous ECG monitoring patches that patients wear at home have been found to significantly increase detection of atrial fibrillation (AF), according to an industry-funded study in JAMA. AF can lead to serious heart-related complications, including stroke and heart failure. Small, comfortable, and effective, Biopatch will ensure patients with AF and other cardiac issues receive early diagnosis and preemptive care from their physicians.
